- Home
- PIII vs PPCB Comparison
PIII vs PPCB Comparison
Compare PIII & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIII | PPCB |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 20.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | PPCB |
|---|---|---|
| Price | $4.21 | $0.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | 10.7K | ★ 256.4K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.01 | $0.70 |
| 52 Week High | $14.50 | $145.46 |
Technical Indicators
Market Signals| Indicator | PIII | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 21.04 | N/A |
| Support Level | $5.01 | N/A |
| Resistance Level | $5.20 | N/A |
| Average True Range (ATR) | 0.22 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 2.48 | 0.00 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.